Penumbra (PEN) Scheduled to Post Earnings on Tuesday

Penumbra (NYSE:PEN) is set to issue its quarterly earnings data after the market closes on Tuesday, July 30th. Analysts expect the company to announce earnings of $0.56 per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.01). The business had revenue of $278.70 million during the quarter, compared to analyst estimates of $274.94 million. Penumbra had a net margin of 8.52% and a return on equity of 7.83%. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.23 earnings per share. On average, analysts expect Penumbra to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Penumbra Stock Down 6.1 %

Shares of NYSE:PEN opened at $178.43 on Monday. The company has a market capitalization of $6.92 billion, a price-to-earnings ratio of 75.29, a P/E/G ratio of 1.80 and a beta of 0.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.12 and a quick ratio of 3.51. The business’s 50-day moving average is $186.61 and its 200-day moving average is $217.00. Penumbra has a 1 year low of $170.59 and a 1 year high of $310.51.

Insider Activity at Penumbra

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $207.41, for a total transaction of $124,446.00. Following the sale, the executive vice president now owns 63,488 shares in the company, valued at $13,168,046.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Penumbra news, Director Don W. Kassing sold 170 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $179.99, for a total transaction of $30,598.30. Following the sale, the director now owns 1,005 shares in the company, valued at $180,889.95. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $207.41, for a total value of $124,446.00. Following the completion of the sale, the executive vice president now owns 63,488 shares in the company, valued at approximately $13,168,046.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,970 shares of company stock worth $6,428,404. Insiders own 5.00% of the company’s stock.

Wall Street Analysts Forecast Growth

PEN has been the topic of a number of research reports. Piper Sandler dropped their price target on Penumbra from $290.00 to $260.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 8th. BTIG Research reduced their target price on Penumbra from $265.00 to $232.00 and set a “buy” rating for the company in a report on Monday, July 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a report on Wednesday, May 8th. Truist Financial reduced their target price on Penumbra from $280.00 to $230.00 and set a “buy” rating for the company in a report on Tuesday, July 16th. Finally, Morgan Stanley reduced their target price on Penumbra from $235.00 to $210.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Penumbra presently has an average rating of “Moderate Buy” and a consensus price target of $260.56.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.